Eli Lilly's experimental drug retatrutide yields up to 60-pound weight loss in type 2 diabetes trial
Solo los hechos

Eli Lilly's experimental drug retatrutide yields up to 60-pound weight loss in type 2 diabetes trial

Resumen

Late-stage trials showed retatrutide helped participants with type 2 diabetes lose up to 23% of body weight and improve blood-sugar control, prompting plans for FDA filing next year.

Eli Lilly reported that its experimental GLP-1 drug retatrutide enabled people with type 2 diabetes to lose as much as 60 pounds, roughly 23% of their body weight, in an 80-week trial published in The Lancet. The weight loss exceeds results from earlier GLP-1 agents such as semaglutide and tirzepatide, which achieved up to 10% and 15% reductions respectively in separate studies.

The trial enrolled more than 1,110 adults with an average starting weight of 234 pounds and a body-mass index of about 38. Participants received weekly doses of retatrutide or a placebo. By the study’s end, over half of those on the drug fell below a BMI of 30, the threshold for obesity. The medication also lowered A1C levels by up to 1.6 percentage points, with 40% of participants reaching an A1C below 5.7%, a level considered non-diabetic.

"Retatrutide is truly an advance in diabetes care," said Dr. Susan Spratt, senior medical director at Duke Health, adding that it "rivals gastric bypass surgery without the surgery."

Retatrutide functions as a “triple agonist,” targeting GLP-1, GIP and glucagon, distinguishing it from tirzepatide’s dual-agonist profile. Separate research published in the New England Journal of Medicine indicated similar weight-loss benefits in non-diabetic patients with obesity, with some losing up to 85 pounds after 104 weeks.

Side effects were comparable to other GLP-1 therapies, most commonly gastrointestinal symptoms such as nausea, diarrhea, constipation and vomiting. About 8% of participants on the highest dose discontinued the drug, versus 5% on placebo. Lilly has not yet submitted a New Drug Application but expects to file early next year. The company is also pursuing legal action against entities selling unapproved “research-only” versions of retatrutide.

"The retatrutide data is very exciting," wrote Dr. Michelle Ponder of Duke University, noting that the A1C reductions suggest some patients achieved diabetes remission, though she cautioned the drug may be too potent for individuals with milder disease.

The findings position retatrutide as a potentially transformative option for diabetes management and obesity treatment, pending regulatory review.

Fuente

NBC News

Sigue leyendo, gratis

Crea una cuenta gratis para seguir las noticias. No se requiere tarjeta.